Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced the publication of a peer-reviewed study in Cell Reports Methods, underpinning its epigenomic profiling ...
(A) Gene-based burden test of rare coding-altering mutations (max gnomAD AF ≤ 0.01). (B) Mutation burden analysis of rare pathogenic noncoding mutations (max gnomAD AF ≤ 0.001; predicted deleterious ...
The National Institute on Aging’s Long Life Family Study (LLFS) selected PacBio technology to generate genomic and epigenomic data from as many as 7,800 participants. The effort will rely on PacBio’s ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Omega Therapeutics™, a company pioneering a new category of genomic medicine through epigenomic programming, today announced the completion of an $85 million ...
Biomarkers hold the key to more targeted and timely patient care, yet current tools for analyzing and identifying them often fall short in specificity, sensitivity, or scalability. The complexity of ...
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable epigenomic ...
Study published in ‘Cell Reports Methods’ demonstrates the strength of Tagomics’ platform for epigenomic biomarker discovery and applications in liquid biopsy Activace platform enables targeted, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results